Prognostic Value of Myeloid Differentiation Primary Response 88 and Toll-Like Receptor 4 in Breast Cancer Patients

Purpose

Breast cancer remains a major cause of death in women worldwide, and tumor metastasis is the leading cause of death in breast cancer patients after conventional treatment. Chronic inflammation is often related to the occurrence and growth of various malignancies. This study evaluated the prognosis of breast cancer patients based on contributors to the innate immune response: myeloid differentiation primary response 88 (MyD88) and Toll-like receptor 4 (TLR4).

Methods

We analyzed data from 205 breast invasive ductal carcinoma (IDC) patients who were treated at the Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, from 2002 to 2006. Overall survival (OS) and disease-free survival (DFS) were compared.

Results

In total, 152 patients (74.15%) were disease-free without relapse or metastasis, whereas 53 (25.85%) patients developed recurrence or metastasis. A significant positive correlation was observed between MyD88 and TLR4 expression (p<0.001). Patients with high expression were more likely to experience death and recurrence/metastasis events (p<0.05). Patients with low MyD88 or TLR4 expression levels had better DFS and OS than patients with high expression levels (log-rank test: p<0.001). Patients with low MyD88 and TLR4 expression levels had better DFS and OS than patients with high expression levels of either (log-rank test: p<0.001). In a multivariate analysis, high MyD88 expression was an independent predictive factor for decreased DFS (adjusted HR, 3.324; 95% CI, 1.663–6.641; p = 0.001) and OS (adjusted HR, 4.500; 95% CI, 1.546–13.098; p = 0.006).

Conclusions

TLR4-MyD88 signaling pathway activation or MyD88 activation alone may be a risk factor for poor prognosis in breast cancer. Therefore, TLR4-MyD88 signaling pathway activation in tumor biology provides a novel potential target for breast cancer therapy.     

Nucleoredoxin Negatively Regulates Toll-like Receptor 4 Signaling via Recruitment of Flightless-I to Myeloid Differentiation Primary Response Gene (88)

We previously characterized nucleoredoxin (NRX) as a negative regulator of the Wnt signaling pathway through Dishevelled (Dvl). We perform a comprehensive search for other NRX-interacting proteins and identify Flightless-I (Fli-I) as a novel NRX-binding partner. Fli-I binds to NRX and other related proteins, such as Rod-derived cone viability factor (RdCVF), whereas Dvl binds only to NRX. Endogenous NRX and Fli-I in vivo interactions are confirmed. Both NRX and RdCVF link Fli-I with myeloid differentiation primary response gene (88) (MyD88), an important adaptor protein for innate immune response. NRX and RdCVF also potentiate the negative effect of Fli-I upon lipopolysaccharide-induced activation of NF-κB through the Toll-like receptor 4/MyD88 pathway. Embryonic fibroblasts derived from NRX gene-targeted mice show aberrant NF-κB activation upon lipopolysaccharide stimulation. These results suggest that the NRX subfamily of proteins forms a link between MyD88 and Fli-I to mediate negative regulation of the Toll-like receptor 4/MyD88 pathway.     

胆固醇逆转运相关蛋白基因在骨骼肌的表达

构建载脂蛋白ＡＩ（ａｐｏＡＩ）、载脂蛋白Ｅ（ａｐｏＥ）和卵磷脂胆固醇酰基转移酶（ＬＣＡＴ）的病毒或非病毒载体,分别转染离体成肌细胞或直接注入小鼠骨骼肌,观察其表达程序及分泌人血等情况,探讨借用骨骼肌异源表达这些在胆固醇逆转运中起关键作用的重要候选基因,进而发展一种简易安全基因治疗方法的可能性。结果显示,质粒表达载体ｐＣＭＶａｐｏＥ３和重组腺病毒载体Ａｄ－ＲＳＶ－ａｐｏＡＩ在原代培养小鼠成肌细胞和成     

R753Q Polymorphism Inhibits Toll-like Receptor (TLR) 2 Tyrosine Phosphorylation,Dimerization with TLR6, and Recruitment of Myeloid Differentiation Primary Response Protein 88

The R753Q polymorphism in the Toll-IL-1 receptor domain of Toll-like receptor 2 (TLR2) has been linked to increased incidence of tuberculosis and other infectious diseases, but the mechanisms by which it affects TLR2 functions are unclear. Here, we studied the impact of the R753Q polymorphism on TLR2 expression, hetero-dimerization with TLR6, tyrosine phosphorylation, and recruitment of myeloid differentiation primary response protein (MyD) 88 and MyD88 adapter-like (Mal). Complementation of HEK293 cells with transfected WT or R753Q TLR2 revealed their comparable total levels and only minimal changes in cell surface expression of the mutant species. Notably, even a 100-fold increase in amounts of transfected R753Q TLR2 versus WT variant did not overcome the compromised ability of the mutant TLR2 to activate nuclear factor κB (NF-κB), indicating that a minimal decrease in cell surface levels of the R753Q TLR2 cannot account for the signaling deficiency. Molecular modeling studies suggested that the R753Q mutation changes the electrostatic potential of the DD loop and results in a discrete movement of the residues critical for protein-protein interactions. Confirming these predictions, biochemical assays demonstrated that R753Q TLR2 exhibits deficient agonist-induced tyrosine phosphorylation, hetero-dimerization with TLR6, and recruitment of Mal and MyD88. These proximal signaling deficiencies correlated with impaired capacities of the R753Q TLR2 to mediate p38 phosphorylation, NF-κB activation, and induction of IL-8 mRNA in transfected HEK293 cells challenged with inactivated Mycobacterium tuberculosis or mycobacterial components. Thus, the R753Q polymorphism renders TLR2 signaling-incompetent by impairing its tyrosine phosphorylation, dimerization with TLR6, and recruitment of Mal and MyD88.     

Myeloid Differentiation Factor 88 (MyD88)-Deficiency Increases Risk of Diabetes in Mice

Background

Multiple lines of evidence suggest innate immune response pathways to be involved in the development of obesity-associated diabetes although the molecular mechanism underling the disease is unknown. Recent observations suggest that saturated fatty acids can act as a ligand for toll-like receptor (TLR) 4, which is thought to mediate obesity-associated insulin resistance. Myeloid differentiation factor 88 (MyD88) is an adapter protein for TLR/IL-1 receptor signaling, which is involved in the activation of inflammatory pathways. To evaluate molecular mechanisms linking obesity-associated diabetes down-stream of TLR4, we investigated physiological role of MyD88 in high-fat diet (HFD)-induced obesity.

Methodology/Principal Findings

In the present study, we found MyD88-deficient mice fed a HFD had increased circulating levels of insulin, leptin and cholesterol, as well as liver dysfunction (increased induction of ALT levels, increased activation of JNK and cleavage of PARP), which were linked to the onset of severe diabetes. On the other hand, TNF-α would not be involved in HFD-induced diabetes in MyD88-deficient mice, because TNF-α level was attenuated in MyD88-deficient mice fed with HFD.

Conclusions/Significance

The present finding of an unexpected role for MyD88 in preventing diabetes may provide a potential novel target/strategy for treating metabolic syndrome.     

高密度脂蛋白受体(SR-BI)和胆固醇逆转运

近十几年来对小鼠的B类I型清道夫受体(SRBI)的研究,发现它是一种高亲和力的高密度脂蛋白受体,主要在肝脏和类固醇源性组织中表达。该受体能介导胆固醇酯的选择性吸收,在高密度脂蛋白(HDL)的代谢和胆固醇的“逆转运”中起重要作用。动物实验证明SRBI的表达可减少动脉粥样硬化的发生。如果SRBI对人有相似的作用,它将成为一个好的作用靶点用于临床心脑血管疾病的治疗 。     

猪髓样分化因子MyD88特异性shRNA干扰载体的构建筛选及干扰效果评价

髓样分化因子My D88(myeloid differentiation factor 88)信号通路是一个具有多种调节功能的传导通路,在免疫反应、炎症反应及肿瘤的发生和发展过程中均发挥重要作用。构建猪(Sus scrofa)My D88基因的shRNA干扰载体,并在转录水平和蛋白质表达水平对其干扰效果进行验证,以筛选出干扰效果最优的干扰载体。根据猪My D88基因(Gen Bank登录号:KC766424.1)全长c DNA序列,利用Invitrogen公司在线设计软件设计出4对shRNA干扰序列,退火成双链后,分别将其插入到p Yr-1.1载体中,构建My D88基因的shRNA真核表达载体p Yr-1.1-pig My D88-sh1、p Yr-1.1-pig My D88-sh2、p Yr-1.1-pig My D88-sh3、p Yr-1.1-pig My D88-sh4,并通过双酶切和测序对其进行鉴定。构建成功后转染猪肺泡巨噬细胞3D4/2,通过Real-time PCR及Western blot验证My D88基因的表达水平,以及对LPS刺激后炎症因子TNF-α基因表达水平的影响。结果表明,所构建的猪My D88基因的特异性shRNA表达载体均可显著降低猪My D88 mRNA和蛋白质的表达水平(P0.05),干扰效率分别达到36%、67%、60%、69%;相比于未干扰组,LPS刺激My D88沉默之后的巨噬细胞,炎症因子TNF-α基因表达水平显著下降(P0.05),表明所构建猪My D88干扰载体干扰效果较好。     

Identification and Function of Myeloid Differentiation Factor 88 (MyD88) in Litopenaeus vannamei

Myeloid differentiation factor 88 (MyD88) is a universal and essential signaling protein in Toll-like receptor/interleukin-1 receptor-induced activation of nuclear factor-kappa B. In this study, two MyD88 protein variants (LvMyD88 and LvMyD88-1) were identified in Litopenaeus vannamei. The LvMyD88 cDNA is 1,848 bp in length and contains an open reading frame (ORF) of 1,428 bp, whereas the LvMyD88-1 cDNA is 1,719 bp in length and has an ORF of 1,299 bp. Both variants encode proteins with death and Toll/interleukin-1 receptor domains and share 91% sequence identity. In healthy L. vannamei, the LvMyD88 genes were highly expressed in hemocytes but at a low level in the hepatopancreas. The LvMyD88s expression was induced in hemocytes after challenge with lipopolysaccharide, CpG-ODN2006, Vibrio parahaemolyticus, Staphyloccocus aureus, and white spot syndrome virus, but not by poly I∶C. Overexpression of LvMyD88 and LvMyD88-1 in Drosophila Schneider 2 cells led to activation of antimicrobial peptide genes and wsv069 (ie1), wsv303, and wsv371. These results suggested that LvMyD88 may play a role in antibacterial and antiviral response in L. vannamei. To our knowledge, this is the first report on MyD88 in shrimp and a variant of MyD88 gene in invertebrates.     

Abdominal Distension and Escherichia coli Peritonitis in Mice Lacking Myeloid Differentiation Factor 88

Here we describe the gross and microscopic findings of naturally occurring, β-hemolytic Escherichia coli peritonitis in B6.129-Myd88^tm1Aki male and female mice. Over approximately 5 mo, 10 homozygous mutant mice deficient in myeloid differentiation factor 88 (C57BL/6 strain; male and female) that had not been used in research protocols developed rapid-onset abdominal swelling associated with copious viscous ascites. Each mouse developed an anterior peritonitis, primarily involving the parietal peritoneum and the visceral surface of the spleen, liver, diaphragm, and stomach. Inflammation was confined to the organ surfaces, with no indication of septicemia or grossly apparent gastrointestinal perforation or other tissue compromise that would initiate peritonitis. Peritonitis was likely attributable to compromised antibacterial innate immunity; cohoused, similarly immunodeficient littermates did not develop similar clinical signs. An unusual finding in all cases was mesothelial cell hyperplasia and hypertrophy. Although the underlying innate immune deficiency accounts for much of the observed pathology, the remarkable mesothelial cell morphology and the episodic nature of the peritonitis in some littermates and not others remain unexplained.Abbreviations: MyD88, myeloid differentiation response 88; TLR, Toll-like receptorMice deficient in myeloid differentiation factor 88 (myD88) are commonly studied in immunologic research as models of various diseases, including inflammatory bowel disease and diabetes.^2,3 MyD88 is a key signal transduction molecule for most of the Toll-like receptors (TLR) and IL1 family receptors, initiating cytokine release essential for effective innate immunity.¹⁸ The loss of this adapter protein impairs production of IL1, IL6, IL18, macrophage inhibitory proteins 1 and 2, and various chemokines.^1,12,14 Knockout mutant mice are especially susceptible to gram-negative bacteria, because TLR4, which triggers signaling through MyD88, mediates responses to LPS.^7,17 These immunologic mutants are common in research animal colonies, but their development of clinical signs and lesions consistent with Escherichia coli peritonitis, which arose at different times and affected only some of the immunodeficient mice, was previously unknown.     

High Density Lipoproteins Phosphatidylcholine as a Regulator of Reverse Cholesterol Transport

Russian Journal of Bioorganic Chemistry - Among blood plasma lipoproteins that transport lipids in the organism, a significant role belongs to high-density lipoproteins (HDL). They protect against...     

International Symposium on Reverse Cholesterol Transport. Report on a meeting

The purpose of this symposium was to provide a forum for the reporting of recent findings and the exchange of ideas concerning reverse cholesterol transport, an area of intense interest and some controversy. Data from epidemiological studies have consistently shown that elevated levels of high density lipoproteins (HDL) are an index of increased protection against coronary heart disease. However, the mechanism whereby HDL is involved in the prevention and/or reversal of atherosclerosis is unknown. According to one of the hypotheses, HDL acts as the primary acceptor of unesterified cholesterol from cells and functions jointly with the enzyme lecithin:cholesterol acyltransferase (LCAT) and the cholesteryl ester transfer protein (CETP) to facilitate the movement of cholesterol from peripheral tissues to the plasma and ultimately to the liver. Although this mechanism as originally proposed by Glomset is an essential physiological mechanism, the clinical significance of this hypothesis remains unsubstantiated. Key elements of knowledge are lacking that would allow the linking of cholesterol efflux from cells and tissues with specific events in HDL metabolism, particularly those that are relevant to the prevention and/or reversal of atherosclerosis. Because of the intricate nature of the interaction between the components of reverse cholesterol transport, a conference involving the leading investigators of the field, where extensive discussion of the findings and ideas is allowed, appeared highly desirable. Indeed, from the distance of nearly 4 months, feedback from the participants indicates that the meeting was highly successful and the organizers feel that all the projected goals of the symposium were accomplished.     

Notch1 and Notch2 Inhibit Myeloid Differentiation in Response to Different Cytokines

We have compared the ability of two mammalian Notch homologs, mouse Notch1 and Notch2, to inhibit the granulocytic differentiation of 32D myeloid progenitor cells. 32D cells undergo granulocytic differentiation when stimulated with either granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF). Expression of the activated intracellular domain of Notch1 inhibits the differentiation induced by G-CSF but not by GM-CSF; conversely, the corresponding domain of Notch2 inhibits differentiation in response to GM-CSF but not to G-CSF. The region immediately C-terminal to the cdc10 domain of Notch confers cytokine specificity on the cdc10 domain. The cytokine response patterns of Notch1 and Notch2 are transferred with this region, which we have termed the Notch cytokine response (NCR) region. The NCR region is also associated with differences in posttranslational modification and subcellular localization of the different Notch molecules. These findings suggest that the multiple forms of Notch found in mammals have structural differences that allow their function to be modulated by specific differentiation signals.     

Multidrug Transport Protein NorM from Vibrio cholerae Simultaneously Couples to Sodium- and Proton-Motive Force

Membrane transporters belonging to the multidrug and toxic compound extrusion family mediate the efflux of unrelated pharmaceuticals from the interior of the cell in organisms ranging from bacteria to human. These proteins are thought to fall into two classes that couple substrate efflux to the influx of either Na⁺ or H⁺. We studied the energetics of drug extrusion by NorM from Vibrio cholerae in proteoliposomes in which purified NorM protein was functionally reconstituted in an inside-out orientation. We establish that NorM simultaneously couples to the sodium-motive force and proton-motive force, and biochemically identify protein regions and residues that play important roles in Na⁺ or H⁺ binding. As the positions of protons are not available in current medium and high-resolution crystal structures of multidrug and toxic compound extrusion transporters, our findings add a previously unrecognized parameter to mechanistic models based of these structures.     

Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation

RAS mutations are frequently found among acute myeloid leukemia patients (AML), generating a constitutively active signaling protein changing cellular proliferation, differentiation and apoptosis. We have previously shown that treatment of AML patients with high-dose cytarabine is preferentially beneficial for those harboring oncogenic RAS. On the basis of a murine AML cell culture model, we ascribed this effect to a RAS-driven, p53-dependent induction of differentiation. Hence, in this study we sought to confirm the correlation between RAS status and differentiation of primary blasts obtained from AML patients. The gene expression signature of AML blasts with oncogenic NRAS indeed corresponded to a more mature profile compared to blasts with wildtype RAS, as demonstrated by gene set enrichment analysis (GSEA) and real-time PCR analysis of myeloid ecotropic viral integration site 1 homolog (MEIS1) in a unique cohort of AML patients. In addition, in vitro cell culture experiments with established cell lines and a second set of primary AML cells showed that oncogenic NRAS mutations predisposed cells to cytarabine (AraC) driven differentiation. Taken together, our findings show that AML with inv(16) and NRAS mutation have a differentiation gene signature, supporting the notion that NRAS mutation may predispose leukemic cells to AraC induced differentiation. We therefore suggest that promotion of differentiation pathways by specific genetic alterations could explain the superior treatment outcome after therapy in some AML patient subgroups. Whether a differentiation gene expression status may generally predict for a superior treatment outcome in AML needs to be addressed in future studies.     

Normal Differentiation of Myeloid Leukaemic Cells induced by a Differentiation-inducing Protein

VARIOUS types of cells release an inducer for the formation of colonies in vitro with mature differentiated macrophages and granulocytes from single normal undifferentiated haematopoietic cells^1–8. Using purified inducer from a cloned line of mouse fibroblasts, we have shown that this induction requires a protein (MGI) with a molecular weight of 65–70,000 and a low molecular weight co-factor, both secreted by the fibroblasts⁹. Adenine or adenine-containing nucleotides can substitute for the co-factor^9,10. We have also shown that non-purified conditioned medium produced by human cells can induce undifferentiated cells from patients with acute myeloid leukaemia to differentiate into mature granulocytes¹¹.     

Chronic Peripheral Inflammation Causes a Region-Specific Myeloid Response in the Central Nervous System

1. Download : Download high-res image (195KB)
2. Download : Download full-size image